RxDoctor Payments Data

Daniel Berens, DO

Family Medicine · Spearfish, SDNPI 1316201304

Payments from drug & device makers

$287in general payments, 2019–2025

Across 17 payments — averaging $16.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$119
  • Boehringer Ingelheim$52
  • Pfizer$36
  • Exact Sciences$33
  • Globus Medical$29
  • Nevro Corp.$19

What the payments were for

  • Food & beverage$287100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$287 in reported general payments places this provider in the 55th percentile of 408 family medicine providers in South Dakota.

See all family medicine providers in South Dakota

Medicare billing

Part B allowed, 2024
$119,665
Medicare patients
495
Services billed
1,552

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban134$164,117
OzempicSemaglutide137$138,207
JardianceEmpagliflozin82$98,485
TrulicityDulaglutide89$93,386
MounjaroTirzepatide40$47,000
XareltoRivaroxaban33$44,238
Soliqua 100-33Insulin Glargine/Lixisenatide31$36,558
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$34,905
FarxigaDapagliflozin Propanediol21$28,833
RybelsusSemaglutide23$27,680
Tresiba Flextouch U-100Insulin Degludec46$25,403
Tresiba Flextouch U-200Insulin Degludec18$13,068
MyrbetriqMirabegron12$9,884
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr19$9,748
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$8,512

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$119$165,887160 claims
PfizerEliquis$36$164,117134 claims
Boehringer IngelheimJardiance$52$98,48582 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 408 family medicine providers in South Dakota.

Other family medicine in Spearfish

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →